- Business Wire•3 hours agoBiogen’s Regulatory Applications for Nusinersen as a Treatment for Spinal Muscular Atrophy Accepted by FDA and EMA
Biogen today announced that its New Drug Application for nusinersen, an investigational treatment for spinal muscular atrophy , has been accepted by the U.S.
- Business Wire•19 hours ago
Biogen Inc. announced today that it will present at the 25th Annual Credit Suisse Healthcare Conference. The webcast will be live on Monday, November 7, 2016 at 9:00a.m.
Biogen Inc. (BIIB)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Bid||285.87 x 400|
|Ask||286.26 x 100|
|Day's Range||282.83 - 290.47|
|52wk Range||223.02 - 333.65|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||16.17|
|Avg Vol (3m)||1,570,933|
|Dividend & Yield||N/A (N/A)|